Avastin/Tarceva Combo Fails In Second-Line NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry analysts see little consequence, as each is already well-positioned in lung cancer.
You may also be interested in...
Genentech Posts Solid Second Quarter
EPS misses consensus, but sales of most products modestly estimates.
Avastin Breast Cancer Approval In Spotlight With AVADO
CHICAGO - First placebo-controlled, double-blinded evidence for bevacizumab in first-line metastatic breast cancer presented at ASCO.
OSI: Tarceva Sales Strong, Data Due This Year In Bid For Wider Label
SATURN should provide more clues on KRAS as efficacy biomarker, CEO says.